# **Martin Rowe**

### List of Publications by Citations

Source: https://exaly.com/author-pdf/9163394/martin-rowe-publications-by-citations.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

150
papers

12,381
62
h-index

109
g-index

153
ext. papers

13,011
ext. citations

9
avg, IF
L-index

#	Paper	IF	Citations
150	Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. <i>Cell</i> , <b>1991</b> , 65, 1107-15	56.2	1041
149	Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkinß disease. <i>Lancet, The,</i> <b>1991</b> , 337, 320-2	40	621
148	Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. <i>Nature</i> , <b>2012</b> , 490, 116-20	50.4	600
147	Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1993</b> , 90, 8479-83	11.5	513
146	Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. <i>Journal of Experimental Medicine</i> , <b>1992</b> , 176, 157-68	16.6	441
145	Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. <i>International Journal of Cancer</i> , <b>1988</b> , 42, 329-38	7.5	394
144	Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1987</b> , 84, 3452-6	11.5	330
143	Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkittß lymphoma cell line. <i>Journal of General Virology</i> , <b>1990</b> , 71 ( Pt 7), 1481-95	4.9	291
142	Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. <i>Journal of Experimental Medicine</i> , <b>1991</b> , 173, 147-58	16.6	261
141	HLA-A11 epitope loss isolates of Epstein-Barr virus from a highly A11+ population. <i>Science</i> , <b>1993</b> , 260, 98-100	33.3	242
140	Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells. <i>Journal of General Virology</i> , <b>1987</b> , 68 ( Pt 6), 1575-86	4.9	241
139	Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-kappaB pathway involving TNF receptor-associated factors. <i>Oncogene</i> , <b>1997</b> , 14, 2899-916	9.2	231
138	Restoration of endogenous antigen processing in Burkittß lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression. <i>European Journal of Immunology</i> , <b>1995</b> , 25, 1374-84	6.1	175
137	Host shutoff during productive Epstein-Barr virus infection is mediated by BGLF5 and may contribute to immune evasion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2007</b> , 104, 3366-71	11.5	172
136	Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2. <i>Journal of Virology</i> , <b>1999</b> , 73, 1023-35	5 <sup>6.6</sup>	168
135	The association of an HPV16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer. <i>Nature Medicine</i> , <b>1995</b> , 1, 464-70	50.5	166
134	Epstein-Barr virus-infected B cells persist in the circulation of acyclovir-treated virus carriers. <i>International Journal of Cancer</i> , <b>1989</b> , 43, 67-71	7.5	147

#### (2008-1991)

133	Restricted Epstein-Barr virus protein expression in Burkitt lymphoma is due to a different Epstein-Barr nuclear antigen 1 transcriptional initiation site. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1991</b> , 88, 6343-7	11.5	137
132	Monoclonal antibodies to Epstein-Barr virus-induced, transformation-associated cell surface antigens: binding patterns and effect upon virus-specific T-cell cytotoxicity. <i>International Journal of Cancer</i> , <b>1982</b> , 29, 373-81	7.5	135
131	Epstein-Barr virus-positive Burkitt® lymphoma cells not recognized by virus-specific T-cell surveillance. <i>Nature</i> , <b>1985</b> , 317, 629-31	50.4	131
130	Epstein-Barr virus nuclear antigen 3C interacts with histone deacetylase to repress transcription. Journal of Virology, <b>1999</b> , 73, 5688-97	6.6	131
129	An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in burkitt lymphomagenesis: the Wp/BHRF1 link. <i>PLoS Pathogens</i> , <b>2009</b> , 5, e1000341	7.6	128
128	The Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation. <i>PLoS Pathogens</i> , <b>2009</b> , 5, e1000255	7.6	124
127	T-cell-mediated regression of "spontaneous" and of Epstein-Barr virus-induced B-cell transformation in vitro: studies with cyclosporin A. <i>Cellular Immunology</i> , <b>1984</b> , 87, 646-58	4.4	123
126	Cytostatic effect of Epstein-Barr virus latent membrane protein-1 analyzed using tetracycline-regulated expression in B cell lines. <i>Virology</i> , <b>1996</b> , 223, 29-40	3.6	122
125	Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. <i>Genes and Development</i> , <b>2014</b> , 28, 58-70	12.6	121
124	Immunohistochemical demonstration of the Epstein-Barr virus-encoded latent membrane protein in paraffin sections of Hodgkinß disease. <i>Journal of Pathology</i> , <b>1992</b> , 166, 1-5	9.4	115
123	The H3K27me3 demethylase, KDM6B, is induced by Epstein-Barr virus and over-expressed in Hodgkinß Lymphoma. <i>Oncogene</i> , <b>2011</b> , 30, 2037-43	9.2	112
122	The switch from latent to productive infection in epstein-barr virus-infected B cells is associated with sensitization to NK cell killing. <i>Journal of Virology</i> , <b>2007</b> , 81, 474-82	6.6	112
121	Distinctions between endemic and sporadic forms of Epstein-Barr virus-positive Burkittß lymphoma. <i>International Journal of Cancer</i> , <b>1985</b> , 35, 435-41	7.5	110
120	Ligation of the CD23,p45 (BLAST-2,EBVCS) antigen triggers the cell-cycle progression of activated B lymphocytes. <i>European Journal of Immunology</i> , <b>1986</b> , 16, 1075-80	6.1	109
119	Three transcriptionally distinct forms of Epstein-Barr virus latency in somatic cell hybrids: cell phenotype dependence of virus promoter usage. <i>Virology</i> , <b>1992</b> , 187, 189-201	3.6	106
118	Epstein-Barr virus latent membrane protein-1 (LMP1) C-terminus activation region 2 (CTAR2) maps to the far C-terminus and requires oligomerisation for NF-kappaB activation. <i>Oncogene</i> , <b>1997</b> , 15, 1851	-8 <sup>9.2</sup>	105
117	Epstein-Barr virus-specific cytotoxic T-cell clones restricted through a single HLA antigen. <i>Nature</i> , <b>1982</b> , 297, 413-5	50.4	98
116	Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products. <i>Seminars in Cancer Biology</i> , <b>2008</b> , 18, 397-408	12.7	94

115	Expression of Epstein-Barr virus replicative proteins in AIDS-related non-Hodgkinß lymphoma cells. Journal of Pathology, <b>1991</b> , 165, 289-99	9.4	93
114	Features distinguishing Epstein-Barr virus infections of epithelial cells and B cells: viral genome expression, genome maintenance, and genome amplification. <i>Journal of Virology</i> , <b>2009</b> , 83, 7749-60	6.6	92
113	Human cytotoxic T-cell responses against Epstein-Barr virus nuclear antigens demonstrated by using recombinant vaccinia viruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1990</b> , 87, 2906-10	11.5	92
112	Evidence for an association between CD23 and the receptor for a low molecular weight B cell growth factor. <i>European Journal of Immunology</i> , <b>1986</b> , 16, 1627-30	6.1	92
111	Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. <i>Journal of Immunology</i> , <b>2001</b> , 167, 5420-8	5.3	88
110	The Epstein-Barr virus carrier state: dominance of a single growth-transforming isolate in the blood and in the oropharynx of healthy virus carriers. <i>Journal of General Virology</i> , <b>1991</b> , 72 ( Pt 7), 1579-90	4.9	88
109	Quantitative studies of Epstein-Barr virus-encoded microRNAs provide novel insights into their regulation. <i>Journal of Virology</i> , <b>2011</b> , 85, 996-1010	6.6	87
108	Epstein-Barr virus status and tumour cell phenotype in sporadic Burkittß lymphoma. <i>International Journal of Cancer</i> , <b>1986</b> , 37, 367-73	7.5	84
107	Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised. <i>Journal of Experimental Medicine</i> , <b>1995</b> , 181, 2221-8	16.6	83
106	Burkittß lymphoma: the Rosetta Stone deciphering Epstein-Barr virus biology. <i>Seminars in Cancer Biology</i> , <b>2009</b> , 19, 377-88	12.7	80
105	The DNase of gammaherpesviruses impairs recognition by virus-specific CD8+ T cells through an additional host shutoff function. <i>Journal of Virology</i> , <b>2008</b> , 82, 2385-93	6.6	79
104	Epstein-Barr virus nuclear antigen 3C and prothymosin alpha interact with the p300 transcriptional coactivator at the CH1 and CH3/HAT domains and cooperate in regulation of transcription and histone acetylation. <i>Journal of Virology</i> , <b>2002</b> , 76, 4699-708	6.6	79
103	Epstein-Barr virus infection of polarized epithelial cells via the basolateral surface by memory B cell-mediated transfer infection. <i>PLoS Pathogens</i> , <b>2011</b> , 7, e1001338	7.6	78
102	The bfl-1 gene is transcriptionally upregulated by the Epstein-Barr virus LMP1, and its expression promotes the survival of a Burkittß lymphoma cell line. <i>Journal of Virology</i> , <b>2000</b> , 74, 6652-8	6.6	78
101	Down-regulation of BLIMP1 by the EBV oncogene, LMP-1, disrupts the plasma cell differentiation program and prevents viral replication in B cells: implications for the pathogenesis of EBV-associated B-cell lymphomas. <i>Blood</i> , <b>2011</b> , 117, 5907-17	2.2	76
100	Bmi-1 is induced by the Epstein-Barr virus oncogene LMP1 and regulates the expression of viral target genes in Hodgkin lymphoma cells. <i>Blood</i> , <b>2007</b> , 109, 2597-603	2.2	76
99	Epstein-Barr virus LMP1 blocks p16INK4a-RB pathway by promoting nuclear export of E2F4/5. Journal of Cell Biology, <b>2003</b> , 162, 173-83	7:3	73
98	Epigenetic and transcriptional changes which follow Epstein-Barr virus infection of germinal center B cells and their relevance to the pathogenesis of Hodgkinß lymphoma. <i>Journal of Virology</i> , <b>2011</b> , 85, 9568-77	6.6	7 <sup>2</sup>

#### (1982-2009)

97	Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle. <i>PLoS Pathogens</i> , <b>2009</b> , 5, e1000490	7.6	68
96	Epstein-Barr virus gp42 is posttranslationally modified to produce soluble gp42 that mediates HLA class II immune evasion. <i>Journal of Virology</i> , <b>2005</b> , 79, 841-52	6.6	68
95	PATTERNS OF EPSTEIN-BARR VIRUS LATENT AND REPLICATIVE GENE EXPRESSION IN EPSTEIN-BARR VIRUS B CELL LYMPHOPROLIFERATIVE DISORDERS AFTER ORGAN TRANSPLANTATION. <i>Transplantation</i> , <b>1994</b> , 58, 317-323	1.8	66
94	Downregulated expression of SHP-1 in Burkitt lymphomas and germinal center B lymphocytes. Journal of Experimental Medicine, <b>1997</b> , 186, 1575-83	16.6	65
93	Latent membrane protein 1 of Epstein-Barr virus stimulates processing of NF-kappa B2 p100 to p52. <i>Journal of Biological Chemistry</i> , <b>2003</b> , 278, 51134-42	5.4	64
92	Viral latent membrane protein 1 (LMP-1)Induced CD99 down-regulation in B cells leads to the generation of cells with Hodgkinß and Reed-Sternberg phenotype. <i>Blood</i> , <b>2000</b> , 95, 294-300	2.2	64
91	Epstein-Barr virus-transformed human precursor B cell lines: altered growth phenotype of lines with germ-line or rearranged but nonexpressed heavy chain genes. <i>European Journal of Immunology</i> , <b>1987</b> , 17, 1199-207	6.1	64
90	Reactivation of Epstein-Barr virus-specific cytotoxic T cells by in vitro stimulation with the autologous lymphoblastoid cell line. <i>International Journal of Cancer</i> , <b>1981</b> , 27, 593-601	7.5	64
89	The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and class II molecules. <i>Journal of Virology</i> , <b>2002</b> , 76, 8179-88	6.6	63
88	Two carboxyl-terminal activation regions of Epstein-Barr virus latent membrane protein 1 activate NF-kappaB through distinct signaling pathways in fibroblast cell lines. <i>Journal of Biological Chemistry</i> , <b>2003</b> , 278, 46565-75	5.4	60
87	Epstein-Barr virus LMP-1 natural sequence variants differ in their potential to activate cellular signaling pathways. <i>Journal of Virology</i> , <b>2001</b> , 75, 9129-41	6.6	60
86	Cytotoxic T cell recognition of Epstein-Barr virus-infected B cells. III. Establishment of HLA-restricted cytotoxic T cell lines using interleukin 2. <i>European Journal of Immunology</i> , <b>1982</b> , 12, 1012	8 <sup>-1</sup>	60
85	The Epstein-Barr virus-encoded BILF1 protein modulates immune recognition of endogenously processed antigen by targeting major histocompatibility complex class I molecules trafficking on both the exocytic and endocytic pathways. <i>Journal of Virology</i> , <b>2011</b> , 85, 1604-14	6.6	58
84	Impaired transporter associated with antigen processing-dependent peptide transport during productive EBV infection. <i>Journal of Immunology</i> , <b>2005</b> , 174, 6829-38	5.3	57
83	Unexpected patterns of Epstein-Barr virus transcription revealed by a high throughput PCR array for absolute quantification of viral mRNA. <i>Virology</i> , <b>2015</b> , 474, 117-30	3.6	55
82	Latent membrane protein 1 inhibits Epstein-Barr virus lytic cycle induction and progress via different mechanisms. <i>Journal of Virology</i> , <b>2003</b> , 77, 5000-7	6.6	55
81	A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy. <i>Blood</i> , <b>2010</b> , 116, 3695-704	2.2	54
80	Stimulation of human lymphocytes with irradiated cells of the autologous Epstein-Barr virus-transformed cell line. I. Virus-specific and nonspecific components of the cytotoxic response. <i>Cellular Immunology</i> , <b>1982</b> , 67, 129-40	4.4	54

79	Epstein-Barr virus latent membrane protein-1 (LMP1) signalling is distinct from CD40 and involves physical cooperation of its two C-terminus functional regions. <i>Oncogene</i> , <b>1998</b> , 17, 2383-92	9.2	53
78	Phosphatidylinositol 3-kinase is essential for the proliferation of lymphoblastoid cells. <i>Oncogene</i> , <b>2002</b> , 21, 1263-71	9.2	52
77	Epstein-Barr virus evades CD4+ T cell responses in lytic cycle through BZLF1-mediated downregulation of CD74 and the cooperation of vBcl-2. <i>PLoS Pathogens</i> , <b>2011</b> , 7, e1002455	7.6	51
76	Epstein-Barr Virus and Carcinomas Expression of the Viral Genome in an Undifferentiated Gastric Carcinoma. <i>Diagnostic Molecular Pathology</i> , <b>1992</b> , 1, 103-108		49
75	Precipitation of the Epstein-Barr virus protein EBNA 2 by an EBNA 3c-specific monoclonal antibody. Journal of General Virology, <b>1994</b> , 75 ( Pt 4), 769-78	4.9	48
74	Nuclear factor kappa B-dependent activation of the antiapoptotic bfl-1 gene by the Epstein-Barr virus latent membrane protein 1 and activated CD40 receptor. <i>Journal of Virology</i> , <b>2004</b> , 78, 1800-16	6.6	47
73	The role of repetitive DNA sequences in the size variation of Epstein-Barr virus (EBV) nuclear antigens, and the identification of different EBV isolates using RFLP and PCR analysis. <i>Journal of General Virology</i> , <b>1995</b> , 76 ( Pt 4), 779-90	4.9	46
72	Epstein Barr virus entry; kissing and conjugation. Current Opinion in Virology, 2014, 4, 78-84	7.5	45
71	Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults characterized by high viral genome load within circulating natural killer cells. <i>Clinical Infectious Diseases</i> , <b>2010</b> , 51, 66-9	11.6	44
70	Mechanism of action of a novel latent membrane protein-1 dominant negative. <i>Journal of Biological Chemistry</i> , <b>2001</b> , 276, 1195-203	5.4	44
69	The 30-base-pair deletion in Chinese variants of the Epstein-Barr virus LMP1 gene is not the major effector of functional differences between variant LMP1 genes in human lymphocytes. <i>Journal of Virology</i> , <b>1998</b> , 72, 4038-48	6.6	44
68	The Epstein-Barr virus:host balance in acute infectious mononucleosis patients receiving acyclovir anti-viral therapy. <i>International Journal of Cancer</i> , <b>1989</b> , 43, 61-6	7.5	43
67	Lymphotoxin acts as an autocrine growth factor for Epstein-Barr virus-transformed B cells and differentiated Burkitt lymphoma cell lines. <i>European Journal of Immunology</i> , <b>1994</b> , 24, 1879-85	6.1	41
66	The Missing Link in Epstein-Barr Virus Immune Evasion: the BDLF3 Gene Induces Ubiquitination and Downregulation of Major Histocompatibility Complex Class I (MHC-I) and MHC-II. <i>Journal of Virology</i> , <b>2016</b> , 90, 356-67	6.6	40
65	Epstein-Barr virus and Burkitt lymphoma. Chinese Journal of Cancer, 2014, 33, 609-19		40
64	Immune responses to Epstein-Barr virus: molecular interactions in the virus evasion of CD8+ T cell immunity. <i>Microbes and Infection</i> , <b>2010</b> , 12, 173-81	9.3	39
63	HIV-1 induces down-regulation of bcl-2 expression and death by apoptosis of EBV-immortalized B cells: a model for a persistent "self-limiting" HIV-1 infection. <i>Virology</i> , <b>1994</b> , 198, 234-44	3.6	38
62	Isolation of a normal B cell subset with a Burkitt-like phenotype and transformation in vitro with Epstein-Barr virus. <i>International Journal of Cancer</i> , <b>1988</b> , 42, 213-20	7.5	38

## (2001-2001)

61	Characterization of intercellular adhesion molecule-1 regulation by Epstein-Barr virus-encoded latent membrane protein-1 identifies pathways that cooperate with nuclear factor kappa B to activate transcription. <i>Journal of Biological Chemistry</i> , <b>2001</b> , 276, 984-92	5.4	36
60	Cooperation between Epstein-Barr virus immune evasion proteins spreads protection from CD8+ T cell recognition across all three phases of the lytic cycle. <i>PLoS Pathogens</i> , <b>2014</b> , 10, e1004322	7.6	33
59	Deciphering the role of Epstein-Barr virus in the pathogenesis of T and NK cell lymphoproliferations. <i>Herpesviridae</i> , <b>2011</b> , 2, 8		33
58	Characterization of the serological response in man to the latent membrane protein and the six nuclear antigens encoded by Epstein-Barr virus. <i>Journal of General Virology</i> , <b>1988</b> , 69 ( Pt 6), 1217-28	4.9	33
57	Epstein-Barr virus transcription factor Zta acts through distal regulatory elements to directly control cellular gene expression. <i>Nucleic Acids Research</i> , <b>2015</b> , 43, 3563-77	20.1	28
56	Suppression of the LMP2A target gene, EGR-1, protects Hodgkinß lymphoma cells from entry to the EBV lytic cycle. <i>Journal of Pathology</i> , <b>2013</b> , 230, 399-409	9.4	27
55	Modulation of B-cell endoplasmic reticulum calcium homeostasis by Epstein-Barr virus latent membrane protein-1. <i>Molecular Cancer</i> , <b>2009</b> , 8, 59	42.1	27
54	Counteracting effects of cellular Notch and Epstein-Barr virus EBNA2: implications for stromal effects on virus-host interactions. <i>Journal of Virology</i> , <b>2014</b> , 88, 12065-76	6.6	26
53	Cyclical expression of EBV latent membrane protein 1 in EBV-transformed B cells underpins heterogeneity of epitope presentation and CD8+ T cell recognition. <i>Journal of Immunology</i> , <b>2009</b> , 182, 1919-28	5.3	26
52	Memory B-cell reconstitution following allogeneic hematopoietic stem cell transplantation is an EBV-associated transformation event. <i>Blood</i> , <b>2015</b> , 126, 2665-75	2.2	25
51	Epstein-Barr virus latent membrane protein 1 increases calcium influx through store-operated channels in B lymphoid cells. <i>Journal of Biological Chemistry</i> , <b>2011</b> , 286, 18583-92	5.4	24
50	Epstein-barr virus and the pathogenesis of T and NK lymphoma: a mystery unsolved. <i>Current Hematologic Malignancy Reports</i> , <b>2012</b> , 7, 276-84	4.4	23
49	Epstein-Barr virus represses the FoxO1 transcription factor through latent membrane protein 1 and latent membrane protein 2A. <i>Journal of Virology</i> , <b>2006</b> , 80, 11191-9	6.6	22
48	Epstein-Barr virus regulates STAT1 through latent membrane protein 1. <i>Journal of Virology</i> , <b>2003</b> , 77, 4439-43	6.6	22
47	Herpesviruses placating the unwilling host: manipulation of the MHC class II antigen presentation pathway. <i>Viruses</i> , <b>2012</b> , 4, 1335-53	6.2	21
46	Effect of the EBNA-2 gene on the surface antigen phenotype of transfected EBV-negative B-lymphoma lines. <i>International Journal of Cancer</i> , <b>1990</b> , 45, 77-82	7.5	20
45	Induction of the Lytic Cycle Sensitizes Epstein-Barr Virus-Infected B Cells to NK Cell Killing That Is Counteracted by Virus-Mediated NK Cell Evasion Mechanisms in the Late Lytic Cycle. <i>Journal of Virology</i> , <b>2016</b> , 90, 947-58	6.6	19
44	CD99 expression is positively regulated by Sp1 and is negatively regulated by Epstein-Barr virus latent membrane protein 1 through nuclear factor-kappaB. <i>Blood</i> , <b>2001</b> , 97, 3596-604	2.2	19

43	Isolation and analysis of two strongly transforming isoforms of the Epstein-Barr-Virus(EBV)-encoded latent membrane protein-1 (LMP1) from a single Hodgkinß lymphoma. <i>International Journal of Cancer</i> , <b>1998</b> , 76, 194-200	7.5	18
42	Innate Immune Recognition of EBV. Current Topics in Microbiology and Immunology, 2015, 391, 265-87	3.3	17
41	Kaposiß sarcoma-associated herpesvirus-encoded viral IRF3 modulates major histocompatibility complex class II (MHC-II) antigen presentation through MHC-II transactivator-dependent and -independent mechanisms: implications for oncogenesis. <i>Journal of Virology</i> , <b>2013</b> , 87, 5340-50	6.6	16
40	Epstein-Barr virus gene expression in post-transplant lymphoproliferative disorders. <i>Seminars in Immunopathology</i> , <b>1998</b> , 20, 389-403		15
39	Epstein-Barr virus induces a distinct form of DNA-bound STAT1 compared with that found in interferon-stimulated B lymphocytes. <i>Journal of General Virology</i> , <b>2007</b> , 88, 1876-1886	4.9	14
38	Coordinated repression of BIM and PUMA by Epstein-Barr virus latent genes maintains the survival of Burkitt lymphoma cells. <i>Cell Death and Differentiation</i> , <b>2018</b> , 25, 241-254	12.7	13
37	Identification of Epstein-Barr Virus Replication Proteins in Burkitt® Lymphoma Cells. <i>Pathogens</i> , <b>2015</b> , 4, 739-51	4.5	13
36	Epstein-Barr Virus Latent Membrane Protein-1 Mediates Upregulation of Tumor Necrosis Factor-α in EBV-Infected T Cells: Implications for the Pathogenesis of Hemophagocytic Syndrome. <i>Journal of Biomedical Science</i> , <b>2003</b> , 10, 146-155	13.3	13
35	Susceptibility of B lymphocytes to adenovirus type 5 infection is dependent upon both coxsackie-adenovirus receptor and alphavbeta5 integrin expression. <i>Journal of General Virology</i> , <b>2005</b> , 86, 1669-1679	4.9	13
34	CD154 tone sets the signaling pathways and transcriptome generated in model CD40-pluricompetent L3055 Burkitt® lymphoma cells. <i>Journal of Immunology</i> , <b>2007</b> , 179, 2705-12	5.3	12
33	NF-kappaB is required for cell death induction by latent membrane protein 1 of Epstein-Barr virus. <i>Cellular Signalling</i> , <b>2003</b> , 15, 423-33	4.9	12
32	Reduced signal transduction through glucocorticoid receptor in Burkittß lymphoma cell lines. <i>Virology</i> , <b>1994</b> , 199, 339-53	3.6	12
31	Epstein-Barr virus latent genes in tumour cells of Hodgkinß disease. Lancet, The, 1991, 337, 1617	40	12
30	EBV BCL-2 homologue BHRF1 drives chemoresistance and lymphomagenesis by inhibiting multiple cellular pro-apoptotic proteins. <i>Cell Death and Differentiation</i> , <b>2020</b> , 27, 1554-1568	12.7	12
29	Sphingosine-1-phosphate signalling drives an angiogenic transcriptional programme in diffuse large B cell lymphoma. <i>Leukemia</i> , <b>2019</b> , 33, 2884-2897	10.7	11
28	Cytogenetic rearrangement of C-MYC oncogene occurs prior to infection with Epstein-Barr virus in the monoclonal malignant B cells from an AIDS patient. <i>Leukemia and Lymphoma</i> , <b>1993</b> , 9, 157-64	1.9	11
27	Stimulation of human lymphocytes with irradiated cells of the autologous Epstein-Barr virus-transformed cell line. II. Cytotoxic response to repeated stimulation. <i>Cellular Immunology</i> , <b>1982</b> , 67, 141-51	4.4	11
26	Hypomethylation and Over-Expression of the Beta Isoform of BLIMP1 is Induced by Epstein-Barr Virus Infection of BICells; Potential Implications for the Pathogenesis of EBV-Associated Lymphomas. <i>Pathogens</i> , <b>2012</b> , 1, 83-101	4.5	10

## (2001-2003)

25	Epstein-barr virus latent membrane protein-1 mediates upregulation of tumor necrosis factor-alpha in EBV-infected T cells: implications for the pathogenesis of hemophagocytic syndrome. <i>Journal of Biomedical Science</i> , <b>2003</b> , 10, 146-55	13.3	10
24	MHC class II-restricted presentation of endogenously synthesized antigen: Epstein-Barr virus transformed B cell lines can present the viral glycoprotein gp340 by two distinct pathways. <i>International Immunology</i> , <b>1993</b> , 5, 451-60	4.9	10
23	Epstein-Barr virus transforming proteins. Seminars in Virology, 1994, 5, 391-399		10
22	Establishment of an EBV-positive lymphoblastoid cell line that grows as a lymphoma in nude mice and expresses membrane CD2 molecules. <i>International Journal of Cancer</i> , <b>1990</b> , 45, 299-307	7.5	10
21	Arginine Methyltransferases Are Regulated by Epstein-Barr Virus in B Cells and Are Differentially Expressed in Hodgkinß Lymphoma. <i>Pathogens</i> , <b>2012</b> , 1, 52-64	4.5	9
20	The level of expression of class-I MHC antigens in adenovirus-transformed human cell lines. <i>International Journal of Cancer</i> , <b>1987</b> , 40, 213-9	7.5	9
19	Induction of interferon-stimulated genes on the IL-4 response axis by Epstein-Barr virus infected human b cells; relevance to cellular transformation. <i>PLoS ONE</i> , <b>2013</b> , 8, e64868	3.7	9
18	STAT1 contributes to the maintenance of the latency III viral programme observed in Epstein-Barr virus-transformed B cells and their recognition by CD8+ T cells. <i>Journal of General Virology</i> , <b>2009</b> , 90, 2239-50	4.9	8
17	Epstein-Barr virus-specific T-cell recognition of B-cell transformants expressing different EBNA 2 antigens. <i>International Journal of Cancer</i> , <b>1987</b> , 39, 373-9	7.5	8
16	Lymphoblastoid cells transfected with c-myc: downregulation of EBV-lytic antigens and impaired response of autologous CD4+ T cells in vitro. <i>International Journal of Cancer</i> , <b>1996</b> , 68, 810-6	7.5	7
15	Cross-recognition of a mouse H-2-peptide complex by human HLA-restricted cytotoxic T cells. <i>European Journal of Immunology</i> , <b>1990</b> , 20, 659-64	6.1	7
14	Analysis of human tumour necrosis factor receptor 1 dominant-negative mutants reveals a major region controlling cell surface expression. <i>FEBS Letters</i> , <b>2004</b> , 570, 138-42	3.8	6
13	Cell transformation induced by Epstein-Barr virusliving dangerously. <i>Seminars in Cancer Biology</i> , <b>2001</b> , 11, 403-5	12.7	6
12	Detection of EBV latent proteins by western blotting. <i>Methods in Molecular Biology</i> , <b>2001</b> , 174, 229-42	1.4	4
11	Selective reactivation of Epstein-Barr virus-specific cytotoxic T cells by stimulation in vitro with allogeneic virus-transformed HLA-homozygous typing cells. <i>Human Immunology</i> , <b>1983</b> , 6, 151-65	2.3	4
10	Burkitt-like lymphoma in an English child: characterisation of tumour biopsy cells and of the derived tumour cell line. <i>British Journal of Cancer</i> , <b>1986</b> , 54, 385-91	8.7	4
9	The Epstein-Barr virus BamHI C promoter is not essential for B cell immortalization in vitro, but it greatly enhances B cell growth transformation. <i>Journal of Virology</i> , <b>2015</b> , 89, 2483-93	6.6	3
8	Characterization of a CD40-dominant inhibitory receptor mutant. <i>Journal of Immunology</i> , <b>2001</b> , 167, 63	8 <del>§.9</del> 3	3

7	Restoration of the LFA-3 adhesion pathway in Burkittß lymphoma cells using an LFA-3 recombinant vaccinia virus: consequences for T cell recognition. <i>European Journal of Immunology</i> , <b>1992</b> , 22, 1741-8	6.1	3
6	Human lymphocyte ecto-5Pnucleotidase is not directly involved in immunoglobulin production [proceedings]. <i>Biochemical Society Transactions</i> , <b>1979</b> , 7, 997-8	5.1	2
5	Three Restricted Forms of Epstein-Barr Virus Latency Counteracting Apoptosis in c-Myc Expressing Burkitt Lymphoma Cells <i>Blood</i> , <b>2007</b> , 110, 1572-1572	2.2	2
4	Viral latent membrane protein 1 (LMP-1)Induced CD99 down-regulation in B cells leads to the generation of cells with Hodgkinß and Reed-Sternberg phenotype. <i>Blood</i> , <b>2000</b> , 95, 294-300	2.2	2
3	Epstein-Barr virus gene expression in post-transplant lymphoproliferative disorders <b>1998</b> , 20, 389		1
2	EBV, molecular mimicry and rheumatoid arthritis: a hypothesis. <i>Immunology Letters</i> , <b>1989</b> , 20, 93	4.1	

Immunity to Oncogenic Viruses **2016**, 363-374